CODX241129P1500
- 0.00
- 0.000.00%
Co-diagnostics Newsroom
WHO Extends Mpox Emergency; Canada Reports First Clade I Case
Trump Nominates Marty Makary For FDA Commissioner
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
First Mpox Case Linked to African Outbreak Reported in U.S.
Sell-off of US vaccine stocks intensifies! Analyst: Little Kennedy brings uncertainty to the entire industry.
1. On Friday Eastern Time, vaccine manufacturers' stocks plummeted as Donald Trump selected vaccine skeptic Kennedy as Health Secretary, causing industry uncertainty. Moderna, Novavax, Pfizer, and other stock prices were all affected. 2. Analysts pointed out that Kennedy's anti-vaccine stance may weaken public trust in vaccines, leading to a decrease in the vaccination rate in the USA, increasing the risk of outbreaks of diseases such as measles and whooping cough.
Vaccines stocks in the usa collectively plummet! Trump surprisingly appoints an anti-vaccine advocate as the Secretary of Health in the usa.
① Trump nominated Robert F. Kennedy Jr. as the new Secretary of Health and Human Services, which triggered a sell-off in vaccine companies; ② Kennedy advocates very radical views, opposing vaccines since 2005, and questioning the transparency of the usa government in public health information.
H.C. Wainwright Maintains Co-diagnostics(CODX.US) With Hold Rating, Maintains Target Price $1.5
Express News | HC Wainwright & Co. Reiterates Neutral on Co-Diagnostics, Maintains $1.5 Price Target
Co-Diagnostics Analyst Ratings
Co-Diagnostics, Inc. (CODX) Q3 2024 Earnings Call Transcript Summary
Co-Diagnostics, Inc. (CODX) Q3 2024 Earnings Call Transcript
Co-Diagnostics GAAP EPS of -$0.32 Beats by $0.01, Revenue of $0.64M Beats by $0.26M
Earnings Flash (CODX) CO-DIAGNOSTICS Posts Q3 Revenue $641,141
Co-diagnostics | 10-Q: Q3 2024 Earnings Report
Co-diagnostics | 8-K: Co-Diagnostics, Inc. Reports Third Quarter 2024 Financial Results
Express News | Co-Diagnostics Q3 Revenue USD 600 Thousand
Co-Diagnostics 3Q Loss/Shr 32c >CODX
Co-Diagnostics, Inc. to Host Booth at MEDICA Trade Fair in Düsseldorf, Germany on Nov 11-14, 2024
Earnings Preview: CODX to Report Financial Results Post-market on November 07
Is Co-Diagnostics (NASDAQ:CODX) In A Good Position To Deliver On Growth Plans?